Ten Drugs Selected for Medicare Price Negotiation to Lower Costs for Millions of Americans.
HHS has reached agreements with all participating manufacturers on new negotiated, lower drug prices for the first 10 drugs selected for the Medicare drug price negotiation program. After manufacturers have steadily increased the list prices of all 10 of these drugs since they went on the market, these new prices will cut the list price of these drugs between 38 and 79 percent.
Here are the 10 drugs and their negotiated prices for a one-month supply:
- Januvia treats diabetes. The negotiated price is $113 (£103), down 79%.
- Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, NovoLog PenFill: These drugs, which are insulin medications, treat diabetes. The negotiated price is $119, down 76%.
- Farxiga treats diabetes, heart failure and chronic kidney disease. The negotiated price is $178.50, down 68 %.
- Enbrel treats rheumatoid arthritis, psoriasis and psoriatic arthritis. The negotiated price is $2,355, down 67%.
- Jardiance treats diabetes, heart failure and chronic kidney disease. The negotiated price is $197, down 66%.
- Stelara treats psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The negotiated price is $4,695, down 66%.
- Xarelto prevents and treats blood clots and reduces risk of coronary or peripheral artery disease. The negotiated price is $197, down 62%.
- Eliquis prevents and treats blood clots. The negotiated price is $23, down 56%.
- Entresto treats heart failure. The negotiated price is $628, down 53%.
- Imbruvica treats blood cancers. The negotiated price is $9,319, down 38%.
Source: CMS, https://www.cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf